{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-25-000104","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.416983+00:00","generated_at":"2026-05-17T21:11:38.281931+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M","bullets":["Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.","Adjusted EPS $0.12 vs $0.05 YoY; adjusted EBITDA $9.3M vs $5.6M; gross margin 74.2% up from 73.8%.","Raised FY25 revenue guidance to at least 17% growth, or $219M; reiterates gross margin 73-75% and net cash flow positive.","FDA accepted BLA for Avance Nerve Graft; PDUFA date Sept 5, 2025; pre-licensing inspection and regulatory milestones completed."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-25-000104","json":"https://secwatch.observer/filing/0000805928-25-000104.json","markdown":"https://secwatch.observer/filing/0000805928-25-000104.md","text":"https://secwatch.observer/filing/0000805928-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000104/0000805928-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000104/axgn-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:11:38.281931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}